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Event Committee. Secondary endpoints, presented here, included a composite
of cardiac deaths and HF hospitalizations and cardiovascular (CV) hospitaliza-
tions, at 3 years. Treatment groups were compared based on an intention-to-
treat principle.
Results: 650 pts were enrolled in 43 centers in 7 countries (72.4±11.2
years, 55.2% males, 52.0% SND, 41.8% intermittent AVB and 6.2% perma-
nent AVB) and implanted with a dual chamber pacemaker. 632 pts were ran-
domized (314 in SafeR and 318 in DDD). Median%Vp was 11.5% in SafeR
vs. 93.6% in DDD (p<0.001). The time to cardiac death or first HF hospital-
ization (figure) and the time to first hospitalization for CV event were both
significantly increased in SafeR vs. DDD group (p=0.018 and p=0.050,
respectively). The duration of hospitalization due to CV reason was signifi-
cantly decreased in SafeR vs. DDD (1.55±5.4 vs. 3.05±11.6 days, p=0.037). 
Conclusion: As compared to DDD, the SafeR pacing mode significantly
increased the time to cardiac death or first HF hospitalization, the time to first
CV hospitalization and significantly reduced the duration of hospitalizations
for any CV reason. 
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Objectives: We evaluated the results of cardiac transplantation according
access modalities.
Methods: Between 2005 and 2012, 562 patients underwent isolated cardiac
transplantation, divided into five groups: patients under left ventricular assist
device ( group LVAD, n=27, 5%), patients under bi-ventricular assist device
(group Bi-VAD, n=25, 4%), patients transplanted under ECMO (group ECMO
n=90, 16%), patients transplanted according the SuperUrgence1 waiting list
without ECMO (group SU1 NOECMO n=131, 23%), patients transplanted on
the standard waiting list (group Liste, n=289, 53%). A comparison between
the periods 2005/2008 and 2009/2012 was made for the groups LVAD+Bi-
VAD, ECMO, SU NOECMO and Liste.
Results: The occurrence of primary graft dysfunction was: 26% (group
LVAD), 44% (group Bi-VAD), 42% (group ECMO), 21% (group SU1
NOECMO), 26% (group Liste). The period analysis showed no change in pri-
mary graft dysfunction over the time: 33% vs 36% (group LVAD+ Bi-VAD),
50% vs. 35% (group ECMO), 23% vs. 20% (group SU1 NOECMO), 28% vs.
24% (group Liste). One-year mortality was: 15% (group LVAD), 20% (group
Bi-VAD), 31% (group ECMO), 23% (group SU1 NOECMO), 28% (group
Liste). Time analysis showed a 1-year mortality decrease during the 2009/
2012 period: 10% vs 27% (group LVAD+ Bi-VAD), 29% vs. 33% (group
ECMO), 17% vs. 30% (group SU1 NOECMO), 20% vs. 34% (group Liste).
Three-year survival was: 81% (group LVAD), 71% (group Bi-VAD), 64%
(group ECMO), 74% (group SU1 NOECMO), 66% (group Liste). 
Conclusion: Actually, stable patients on the standard waiting lists repre-
sent only half the transplantation activity. Patients transplanted under long-
term circulatory support, especially LVAD, have the best results.
Superurgence1 waiting list patients have good results if they not require pre-
transplant ECMO support. Need for a pre-transplant ECMO is associated with
a higher operative mortality. Outcomes improved over the time for every
group of patients. 
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Background: Risk stratification of patients with stable chronic heart
failure (CHF) is critical to better identify those who may benefit the most from
invasive strategies such as heart transplantation. 
Methods: To improve cardiovascular (CV) death prediction in CHF, we
performed a proteomic analysis using high throughput surface enhanced laser
desorption ionization – time of fight – mass spectrometry (SELDI-TOF-MS).
Plasma samples were pre-treated to access the deep proteome. The proteomic
analysis was first performed in a case (CV death within 3 years) /control (sur-
vivors at 3 years) study including 198 patients with a left ventricular ejection
fraction (LVEF) <45%. A proteomic score was developed in this derivation
population using the support vector machine (SVM) method. The score was
then validated in an independent cohort of 309 consecutive patients (CV death
at 3 years) with CHF. 
Results: Altogether, 203 ion m/z peaks were detected. Among them,
42 peaks were significantly differentially expressed between cases and con-
trols after Bonferroni correction (P value at 0.00025). Then, the SVM
method was applied to develop a proteomic score. In the derivation popula-
tion, the score level was higher in cases as compared to controls: 0.7 vs.
0.25 (P=5.10-29). The ROC curve showed an AUC of 0.87 to predict CV
mortality. In the validation population, the score level was still higher in
patients who experienced a CV death as compared to survivors: 0.53 vs.
0.39 (P=0.0002). The ROC curve showed an AUC of 0.68. After adjustment
on confounders (NYHA class, LVEF, BNP, creatinine, Peak VO2), the score
was still significantly associated with CV death (HR=15.1, P=0.007) and it
allowed a significant improvement of CHF patient reclassification. The net
reclassification index (NRI) and the integrated discrimination improvement
(IDI) reach both significant p values.
Conclusion: Proteomic analysis of low abundance plasma proteins is
highly promising to improve CV death risk prediction in CHF.
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